ADVERTISEMENT

Clean Science, Tatva Chintan Pharma, Neogen Chemicals - Innovation Edge: Nirmal Bang Initiates Coverage

Clean Science, Tatva Chintan Pharma, Neogen Chemicals - Innovation Edge: Nirmal Bang Initiates Coverage

<div class="paragraphs"><p>A&nbsp;laboratory technician tests a  chemical solution inside a laboratory. (Photographer: Asim Hafeez/Bloomberg)</p></div>
A laboratory technician tests a chemical solution inside a laboratory. (Photographer: Asim Hafeez/Bloomberg)

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Nirmal Bang Report

India specialty chemicals sector has been a clear outperformer over the last three-four years in terms of earnings delivery and future growth prospects are also promising on the back of accelerated capex.

Themes like ‘China plus one’ and ‘import substitution’ are very much relevant in select pockets and we see respective companies reaping the benefits of the same.

However, in this report, we have mainly covered companies specifically focused on research and development, process innovation and adoption of clean and green chemistry practices in their operations.

We believe that an R&D-centric growth approach has enabled select companies to compete with China in terms of pricing as well as quality without having a matching scale.

Click on the attachment to read the full report:

Nirmal Bang India-Specialty-Chemicals-31-March-2022.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.